Oseltamivir, once blamed for causing seizures in children, might actually reduce such risks.

Story Snapshot

• New research suggests influenza, not oseltamivir, causes neuropsychiatric events.
• Study shows a 50% reduction in events among treated children.
• Findings challenge a 20-year-old belief and regulatory stance.
• Could lead to changes in clinical practice and regulatory policies.

Oseltamivir’s Controversial History

Oseltamivir, commonly known as Tamiflu, has been at the center of medical debate since its approval, especially due to reports of neuropsychiatric events in children. These concerns were primarily fueled by reports from Japan, where over 100 incidents of seizures and other mental disturbances were linked to the drug. A black-box warning was issued by the FDA in 2005, urging caution in its use among children.

These warnings led to hesitancy among healthcare providers and parents, despite the lack of definitive evidence linking the drug to the adverse events. The debate persisted as experts were divided, with some attributing the events to the flu itself rather than the treatment.

New Findings from Vanderbilt

Research conducted by Vanderbilt University provides clarity on this long-standing issue. An analysis of health records from nearly 700,000 children revealed that influenza itself is the primary cause of neuropsychiatric events. The study, published in *JAMA Neurology*, found that children treated with oseltamivir had a 50% reduction in these events, suggesting a protective rather than harmful effect.

The findings align with what many pediatricians suspected: the flu, not oseltamivir, is responsible for the adverse events. This revelation could potentially shift the perspective of regulatory bodies and healthcare providers, encouraging more confident use of the drug in treating pediatric influenza.

Flu drug once blamed for seizures in kids gets a surprising reversal

A long-running debate over Tamiflu’s safety in children may finally be settled. Researchers found that influenza, not the antiviral medication, was linked to serious neuropsychiatric events like seizures and…

— The Something Guy 🇿🇦 (@thesomethingguy) January 6, 2026

Challenging Long-Held Beliefs

The implications of this study are significant. For two decades, the belief that oseltamivir caused seizures in children influenced clinical decisions and parental consent. The research suggests that the black-box warning might have been based on anecdotal evidence without clear causation. With the new data, there is potential for the FDA to reconsider its stance, possibly revising or removing the warning.

This shift could lead to greater acceptance of oseltamivir, improving treatment rates and outcomes for children with influenza. The study also underscores the importance of distinguishing between drug-induced and disease-related adverse events in pharmacovigilance efforts.

Watch:

Impact on Stakeholders

The new findings offer reassurance to various stakeholders. Pediatricians may feel more confident in prescribing oseltamivir, knowing it reduces rather than increases the risk of neuropsychiatric events. Parents and caregivers can feel more secure in their treatment choices, potentially leading to earlier intervention and better outcomes for children.
The pharmaceutical industry, particularly Roche Pharmaceuticals, may see a resurgence in the reputation of oseltamivir.

Regulatory bodies might reconsider their warnings, setting a precedent for how similar cases are approached in the future. This case highlights the need for robust epidemiological data to support regulatory decisions, ensuring that beneficial treatments are not unjustly restricted.

Meet My Healthy Doc – instant answers, anytime, anywhere.

Sources:

Science Daily
FDA Official Statement
PMC Article
Vanderbilt University News
NIH/PMC Article
CIDRAP
Chest Physician